← All trials
NCT06969287
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2025
- Primary completion
- Apr 1, 2027
- Completion date
- Apr 1, 2028
- First posted
- May 13, 2025
- Last posted
- Oct 7, 2025
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Washington University in St. LouisLead sponsor
- National Institute on Aging (NIA)Collaborator
- Washington University in St. LouisOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.